Straits Times Index
3,297.55 -26.98 (-0.81%) Nikkei
38,814.56 +94.09 (+0.24%) Hang Seng
17,941.78 -170.85 (-0.94%) FTSE 100
8,146.86 -16.81 (-0.21%) Bitcoin USD
66,148.66 +1,009.19 (+1.55%) CMC Crypto 200
1,405.02 -12.85 (-0.91%)
RARE Jul 2024 40.000 put
- GlobeNewswire
Ultragenyx Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
NOVATO, Calif., June 13, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultrarare genetic diseases, today announced the pricing of its underwritten public offering of 7,435,898 shares of its common stock at a price to the public of $39.00 per share. In addition, in lieu of issuing common stock to certain investors, the company is offering pre-funded warran
- Zacks
Ultragenyx (RARE) to Seek Accelerated Nod for Rare Disease Drug
Following a fruitful meeting with the FDA, Ultragenyx (RARE) plans to seek accelerated approval for UX111 for the treatment of Sanfilippo syndrome type A.
- Simply Wall St.
Increases to CEO Compensation Might Be Put On Hold For Now at Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)
Key Insights Ultragenyx Pharmaceutical will host its Annual General Meeting on 18th of June CEO Emil Kakkis' total...
